Show simple item record

dc.contributor.authorBaylis, Françoise
dc.contributor.authorFenton, Andrew
dc.date.accessioned2013-02-11T16:06:36Z
dc.date.available2013-02-11T16:06:36Z
dc.date.issued2007
dc.identifier.citationBaylis, F. & Fenton, A. (2007). Chimera research and stem cell therapies for human neurodegenerative disorders. Cambridge Quarterly of Healthcare Ethics, 16, 195-208. DOI:10.1017/S0963180107070211en_US
dc.identifier.urihttp://hdl.handle.net/10222/15969
dc.description.abstractIn April 2005, the U.S. National Academy of Sciences (NAS) published its Guidelines for Human Embryonic Stem Cell Research. These voluntary guidelines are among the most permissive in the world—in a country that prohibits federal funding of research to derive human embryonic stem (hES) cells (cells that can self-renew or differentiate into most cells in the human body). One of the few research prohibitions in the NAS guidelines concerns the creation of certain kinds of human–nonhuman chimeras. A chimera is an organism with a mixture of cells from two different organisms, from the same or different species. Figure 1 provides a useful overview of different types of chimeras.en_US
dc.language.isoenen_US
dc.publisherCambridge University Pressen_US
dc.relation.ispartofCambridge Quarterly of Healthcare Ethics
dc.subjectChimeraen_US
dc.subjectEmbryonic Stem Cell Researchen
dc.subjectBiomedical Ethicsen
dc.titleChimera Research and Stem Cell Therapies for Human Neurodegenerative Disordersen_US
dc.typeArticleen_US
 Find Full text

Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record